1031747-40-6

Basic information

• Product Name: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide
• Synonyms: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide
• CAS NO: 1031747-40-6
• Molecular Weight: 287.167
• Mol File: 1031747-40-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(1031747-40-6)
• EPA Substance Registry System: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(1031747-40-6)

Safety Data

• Hazardous Substances Data: 1031747-40-6(Hazardous Substances Data)

Usage

General Description

N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide is a chemical compound with a complex molecular structure. It contains a cyclopropanecarboxamide group and a phenyl group attached to a boron-containing moiety. The unique combination of these functional groups gives the compound potential applications in organic synthesis, pharmaceuticals, and materials science. The compound's boron-containing structure also imparts it with interesting chemical reactivity and coordination properties that make it useful in various chemical reactions and coordination chemistry studies. However, its precise uses and potential hazards would depend on its specific properties and applications.

Upstream product

• 14372-07-7 N-(3-bromophenyl)cyclopropanecarboxamide 
• 73183-34-3 bis(pinacol)diborane 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 210907-84-9 3-aminophenylboronic acid pinacolate 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 1260151-58-3 N-methyl-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-carboxamide 

Relevant articles and documents

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR3R4 or -OR5; R2 is selected from aryl, heteroaryl, fused aryl- heterocycloalkyl and fused heteroaryl-heterocycloalkyl each of which may be optionally substituted by one or more R8 groups; R3 is H or alkyl; R4 is: (i) cycloalkyl optionally substituted by one or more -NR11R12, -NHCO2R11, -NHCOR11 and -NHSO2R11 groups; or (ii) -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl is a 4, 5 or 6-membered nitrogen-containing group optionally containing one or more CO groups, wherein said heterocycloalkyl is optionally substituted by one or more one or more (CH2)nR7 groups; (iii) -(CH2)n-heteroaryl, wherein said heteroaryl group is optionally substituted by one or more R7 groups; or (iv) alkyl substituted by one or more -NR11R12groups; or R3 and R4 are linked together with the nitrogen to which they are attached to form a 4, 5 or 6-membered heterocycloalkyl group optionally containing one or two further groups selected from CO, O, N and S, and which is optionally further substituted by one or more R7 groups; R5 is selected from alkyl, -(CH2)n-heteroaryl and -(CH2)n-heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl groups are each optionally substituted by one or more R7 groups; each R11 and R12 is independently H or alkyl; and each n is independently an integer from O to 6; for use in treating or preventing a disorder associated with CDPK. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of PfCDPK1.

ANTI-VIRAL COMPOUNDS

Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flavivi